CN101061134B - 可局部施用的抗表情皱纹和与年龄相关的皱纹的活性物质 - Google Patents

可局部施用的抗表情皱纹和与年龄相关的皱纹的活性物质 Download PDF

Info

Publication number
CN101061134B
CN101061134B CN2005800393599A CN200580039359A CN101061134B CN 101061134 B CN101061134 B CN 101061134B CN 2005800393599 A CN2005800393599 A CN 2005800393599A CN 200580039359 A CN200580039359 A CN 200580039359A CN 101061134 B CN101061134 B CN 101061134B
Authority
CN
China
Prior art keywords
acid
benzyl
compound
salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800393599A
Other languages
English (en)
Chinese (zh)
Other versions
CN101061134A (zh
Inventor
D·伊姆费尔德
H·齐格勒
P·维克斯特伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of CN101061134A publication Critical patent/CN101061134A/zh
Application granted granted Critical
Publication of CN101061134B publication Critical patent/CN101061134B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2005800393599A 2004-11-02 2005-11-01 可局部施用的抗表情皱纹和与年龄相关的皱纹的活性物质 Expired - Lifetime CN101061134B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH18092004 2004-11-02
CH1809/04 2004-11-02
PCT/CH2005/000638 WO2006047900A2 (de) 2004-11-02 2005-11-01 Neue topisch anwendbare wirkstoffe gegen mimische und alterabedingt falten

Publications (2)

Publication Number Publication Date
CN101061134A CN101061134A (zh) 2007-10-24
CN101061134B true CN101061134B (zh) 2011-05-11

Family

ID=35841896

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800393599A Expired - Lifetime CN101061134B (zh) 2004-11-02 2005-11-01 可局部施用的抗表情皱纹和与年龄相关的皱纹的活性物质

Country Status (12)

Country Link
US (1) US7964630B2 (enExample)
EP (1) EP1809652B1 (enExample)
JP (1) JP5006789B2 (enExample)
KR (1) KR101227301B1 (enExample)
CN (1) CN101061134B (enExample)
AT (1) ATE466867T1 (enExample)
BR (1) BRPI0517917B1 (enExample)
CA (1) CA2584643C (enExample)
DE (1) DE502005009544D1 (enExample)
ES (1) ES2345667T3 (enExample)
PL (1) PL1809652T3 (enExample)
WO (1) WO2006047900A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240977A1 (en) * 2007-06-20 2010-09-23 Andreas Caduff Method for measuring the response of a tissue to an electromagnetic field
US9815875B2 (en) 2008-02-19 2017-11-14 Myocept Inc. Postsynaptically targeted chemodenervation agents and their methods of use
WO2010003861A1 (en) * 2008-07-08 2010-01-14 Unilever Plc Antiperspirant products
WO2010003781A1 (en) * 2008-07-08 2010-01-14 Unilever Plc Antiperspirant compositions
MX2012001077A (es) * 2009-07-24 2012-06-12 Lipotec Sa Compuestos inhibidores de la contraccion muscular.
JP4666537B1 (ja) * 2010-01-21 2011-04-06 株式会社資生堂 しわ改善用美容セット並びにこれを使用する美容方法
US10149812B2 (en) 2012-04-13 2018-12-11 Activen Cosmetic composition comprising a muconopeptide
WO2013153236A2 (en) 2012-04-13 2013-10-17 Activen Cosmetic composition comprising a muconopeptide
RU2524428C1 (ru) * 2013-01-21 2014-07-27 Общество с ограниченной ответственностью "Синейро" Пептиды и их производные, взаимодействующие с никотиновым ацетилхолиновым рецептором и пригодные для использования в косметологии против мимических и возрастных морщин
CN103570804B (zh) * 2013-09-11 2015-04-15 深圳市维琪医药研发有限公司 一种具皮肤活性的多肽的合成方法
EP3062889A2 (en) 2013-11-01 2016-09-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
RU2551276C1 (ru) * 2014-02-03 2015-05-20 Закрытое Акционерное Общество "Фарм-Синтез" Способ получения диацетата трипептида
US9649266B2 (en) * 2014-05-01 2017-05-16 Anterios, Inc. Methods to treat, prevent, and improve skin conditions
CN104327155A (zh) * 2014-10-20 2015-02-04 张嘎 一种含有15n—l—脯氨酸残基的三肽型减皱化合物及其制备方法和应用
CN104478991B (zh) * 2014-12-10 2018-06-19 深圳市维琪医药研发有限公司 一种新型多肽化合物及其制备方法和其医药应用
KR101710486B1 (ko) * 2015-01-05 2017-02-28 주식회사 앤코스메슈 올리고펩타이드 유도체 및 이를 포함하는 주름개선용 조성물
CN104592348A (zh) * 2015-01-16 2015-05-06 张嘎 一种含有3,4-脱氢-l-脯氨酸残基的三肽减皱化合物及其制备方法和应用
WO2017102588A1 (en) * 2015-12-16 2017-06-22 Dsm Ip Assets B.V. Novel use
ES2899961T3 (es) * 2015-12-16 2022-03-15 Dsm Ip Assets Bv Inhibidores de DPP4 para uso médico y cosmético
CN106187793A (zh) 2016-01-26 2016-12-07 赵鸣 5‑氨基酮戊酸及其衍生物的盐化合物和应用
CN106038385A (zh) * 2016-06-08 2016-10-26 广州市创美时美容化妆品有限公司 一种刺激胶原蛋白生成抵抗皱纹的化妆品组合物
CN107936108A (zh) * 2017-12-05 2018-04-20 陕西慧康生物科技有限责任公司 一种类蛇毒三肽的液相合成方法
CN107857797A (zh) * 2017-12-07 2018-03-30 陕西慧康生物科技有限责任公司 一种类蛇毒三肽的液相片段合成方法
WO2019166347A1 (en) 2018-02-27 2019-09-06 Lipotrue, S.L. Peptides and compositions for use in cosmetics and medicine
JP7620431B2 (ja) 2018-05-24 2025-01-23 ディーエスエム アイピー アセッツ ビー．ブイ． プロリン誘導体の新規の使用
AU2019361942A1 (en) 2018-10-16 2021-06-03 Glo Pharma, Inc. Nicotinic acetylcholine receptor peptide antagonist conotoxin compositions and related methods
CN113045623A (zh) * 2019-12-27 2021-06-29 深圳翰宇药业股份有限公司 一种蛇毒肽syn-ake的液相合成方法
CN110950926B (zh) * 2019-12-31 2020-10-16 山东济肽生物科技有限公司 类蛇毒三肽的液相合成方法
CN114369139B (zh) * 2020-10-14 2024-04-19 成都泰莱康科技有限公司 类蛇毒三肽的制备方法
US11771637B2 (en) 2021-01-22 2023-10-03 The Procter & Gamble Company Skin care composition and method of using the same
US11571378B2 (en) 2021-01-22 2023-02-07 The Procter & Gamble Company Skin care composition and method of using the same
CN115969728B (zh) * 2021-08-16 2025-06-24 深圳市维琪科技股份有限公司 肽衍生物在制备用于皮肤修复紧致的组合物中的新用途
CN114380887A (zh) * 2021-12-09 2022-04-22 深圳翰宇药业股份有限公司 一种类蛇毒三肽的液相片段合成方法
WO2025162944A2 (en) * 2024-01-29 2025-08-07 Dsm Ip Assets B.V. Novel compounds
FR3160325A3 (fr) 2024-03-19 2025-09-26 L'oreal Stabilisation d'une composition comprenant un polyhydroxyacide, un bêta-hydroxyacide et un peptide avec du polyol
WO2025170081A1 (en) 2024-02-05 2025-08-14 L'oreal Stabilization of composition comprising polyhydroxy acid, beta-hydroxy acid and peptide with polyol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169074B1 (en) * 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
EP1180524A1 (en) * 1999-04-23 2002-02-20 Lipotec, S.A. Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966701A (en) * 1973-11-07 1976-06-29 The Dow Chemical Company Fibrinogen peptide derivatives
US4563305A (en) * 1981-01-07 1986-01-07 University Of Miami Radiolabelled substrates for assaying mammalian enzymes
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169074B1 (en) * 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
EP1180524A1 (en) * 1999-04-23 2002-02-20 Lipotec, S.A. Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides

Also Published As

Publication number Publication date
ATE466867T1 (de) 2010-05-15
WO2006047900A2 (de) 2006-05-11
WO2006047900A3 (de) 2006-07-27
KR20070085372A (ko) 2007-08-27
CA2584643C (en) 2013-01-29
ES2345667T3 (es) 2010-09-29
JP2008518978A (ja) 2008-06-05
DE502005009544D1 (de) 2010-06-17
PL1809652T3 (pl) 2010-10-29
EP1809652A2 (de) 2007-07-25
BRPI0517917B1 (pt) 2020-11-10
BRPI0517917A (pt) 2008-10-21
US7964630B2 (en) 2011-06-21
CN101061134A (zh) 2007-10-24
JP5006789B2 (ja) 2012-08-22
CA2584643A1 (en) 2006-05-11
US20090111731A1 (en) 2009-04-30
EP1809652B1 (de) 2010-05-05
KR101227301B1 (ko) 2013-01-29

Similar Documents

Publication Publication Date Title
CN101061134B (zh) 可局部施用的抗表情皱纹和与年龄相关的皱纹的活性物质
TWI499425B (zh) 用於治療和／或照護皮膚、黏膜和／或頭髮的胜肽以及彼之於化妝品或藥學組成物上的用途
US8304393B2 (en) Epithelial cell growth promoter
US20250019400A1 (en) Polypeptide and cosmetic composition or pharmaceutical composition and use thereof
TW201018492A (en) Peptides useful in the treatment and/or care of skin, mucous membranes, scalp and/or hair and their use in cosmetic or pharmaceutical compositions
CN104478991B (zh) 一种新型多肽化合物及其制备方法和其医药应用
WO2023231573A1 (zh) 肽衍生物异构体及其组合物和用途
CN107207566A (zh) 稳定的肽缀合抗坏血酸衍生物、用于制备其的方法和包含其的化妆品组合物
JP2014516972A (ja) 保湿能に優れたペプチド誘導体およびその用途
JP2008534658A (ja) 顔の皺を減らすおよび／または取り除くためのエンケファリン誘導ペプチドを含む化粧品または皮膚用薬剤組成物
KR101667383B1 (ko) 비오틴이 결합된 ｈｅｘａｐｅｐｔｉｄｅ-２ 유도체 및 이의 용도
ES2358605T3 (es) Composición cosmética para estimular la síntesis de las proteínas de la membrana basal.
CN117304265B (zh) 一种皮肤护理多肽、组合物及其应用
KR101553637B1 (ko) 펩타이드 지방산 유도체 및 이를 함유하는 주름 개선용 화장품 조성물
KR101224809B1 (ko) 레티노산 유도체, 이의 제조 방법 및 이를 포함하는 화장품 조성물
KR20180108988A (ko) 인간 섬유아세포에서 콜라겐 합성 촉진 및 콜라겐 분해 효소 활성화 억제를 유도하는 펩타이드를 함유한 화장품 조성물 및 제조방법
HK1237798B (zh) 稳定的肽缀合抗坏血酸衍生物、用於制备其的方法和包含其的化妆品组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: DSM IP ASSETS BV

Free format text: FORMER OWNER: PENTAPHARM AG

Effective date: 20100816

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: BASEL, SWITZERLAND TO: HEERLEN, THE NETHERLANDS

TA01 Transfer of patent application right

Effective date of registration: 20100816

Address after: Holland Heerlen

Applicant after: DSM IP ASSETS B.V.

Address before: Basel, Switzerland

Applicant before: Pentapharm AG

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20110511

CX01 Expiry of patent term